Marketing authorisation holders must comply with standards set out in European Union (EU) directives. The European Medicines Agency (EMA) coordinates inspections to verify this compliance, the results of which are submitted to online databases.
Inspections can be a routine element of a marketing authorisation application or the post-authorisation phase, or they can be requested 'for cause' by the Committee for Medicinal Products for Human Use (CHMP) or a national competent authority. A for cause inspection can be triggered by various factors, such as an assessor’s concern about the validity of data, or a failure to provide all necessary information.
EMA’s responsibilities for each inspection area are similar and include:
- coordinating inspections for the centralised procedure;
- developing EU-wide guidelines on inspections and related procedures;
- preparing guidance through inspectors working groups;
- coordinating advice on the interpretation of requirements.
Compliance in the product lifecycle
|Research and development||Marketing authorisation application||Post-authorisation|
|Quality by design|
|Good laboratory practice (GLP)|
|Good clinical practice (GCP)|
|Good manufacturing practice (GMP) and good distribution practice (GDP)|
|Plasma master files (PMF)|
|Sampling and testing|
|Vaccine antigen master file (VAMF) inspections|
|Mutual recognition agreements|
How useful is this page?
Average rating:Based on 7 ratings
Add your rating:
- See all ratings
1 ratings1 ratings1 ratings0 ratings4 ratings